Both in Pharmaceuticals
UroGen Pharma vs AnaptysBio
Over the past year URGN returned +45.1% and ANAB returned +36.8%; their daily moves had a correlation of 0.11.
URGN +45.1% ANAB +36.8%Growth of $1, one year, split-adjusted
| Metric | URGN | ANAB |
|---|---|---|
| Price | $28.74 | $47.51 |
| Market cap | $1.40B | $1.42B |
| Today | −16.45% | −0.46% |
| 1 month | −30.6% | −0.8% |
| 6 months | +9.5% | −29.5% |
| Year to date | +22.7% | −2.0% |
| 1 year | +39.4% | +31.8% |
| Revenue growth (YoY) | +199.2% | −8.0% |
| Gross margin | 90.9% | 100.0% |
| Net margin | −19.8% | −206.9% |
| P/E (TTM) | — | — |
| Price / sales | 7.4× | 6.1× |
| Net cash | -$85.1M | $286.5M |
| Dividend yield | — | — |
| Volatility (60d) | 54.9% | 40.0% |
| Short % of float | 12.3% | 30.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).